☰

Christopher R. Zito, Ph.D. - Publications

Affiliations: 
2005 Wesleyan University, Middletown, CT, United States 
Area:
Molecular Biology, Biochemistry, Genetics
Tree Info Similar researchers PubMed Report error

29 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Oria VO, Zhang H, Zito CR, Rane CK, Ma XY, Provance OK, Tran TT, Adeniran A, Kluger Y, Sznol M, Bosenberg MW, Kluger HM, Jilaveanu LB. Coupled fibromodulin and SOX2 signaling as a critical regulator of metastatic outgrowth in melanoma. Cellular and Molecular Life Sciences : Cmls. 79: 377. PMID 35737114 DOI: 10.1007/s00018-022-04364-5  0.657
2021 Tran TT, Rane CK, Zito CR, Weiss SA, Jessel S, Lucca L, Lu BY, Oria VO, Adeniran A, Chiang VL, Omay SB, Hafler DA, Kluger HM, Jilaveanu LB. Clinical Significance of PDCD4 in Melanoma by Subcellular Expression and in Tumor-Associated Immune Cells. Cancers. 13. PMID 33801444 DOI: 10.3390/cancers13051049  0.677
2020 Tran TT, Gallezot JD, Jilaveanu LB, Zito C, Turcu G, Lim K, Nabulsi N, Huang H, Huttner A, Kluger HM, Chiang VL, Carson R. [C]Methionine and [C]PBR28 as PET Imaging Tracers to Differentiate Metastatic Tumor Recurrence or Radiation Necrosis. Molecular Imaging. 19: 1536012120968669. PMID 33147119 DOI: 10.1177/1536012120968669  0.609
2020 Weiss SA, Zito C, Tran T, Heishima K, Neumeister V, McGuire J, Adeniran A, Kluger H, Jilaveanu LB. Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases. Journal of Neuro-Oncology. PMID 32974852 DOI: 10.1007/s11060-020-03619-0  0.629
2020 Oria V, Zhang H, Zhu H, Deng G, Zito C, Rane C, Zhang S, Weiss S, Tran T, Adeniran A, Zhang F, Zhou J, Kluger Y, Bosenberg M, Kluger H, et al. 19. PLEKHA5 REGULATES TUMOR GROWTH IN METASTATIC MELANOMA Neuro-Oncology Advances. 2: ii3-ii3. DOI: 10.1093/noajnl/vdaa073.009  0.676
2019 Zhang H, Zhu H, Deng G, Zito CR, Oria VO, Rane CK, Zhang S, Weiss SA, Tran T, Adeniran A, Zhang F, Zhou J, Kluger Y, Bosenberg MW, Kluger HM, et al. PLEKHA5 regulates tumor growth in metastatic melanoma. Cancer. PMID 31769872 DOI: 10.1002/Cncr.32611  0.678
2019 Damsky W, Jilaveanu L, Turner N, Perry C, Zito C, Tomayko M, Leventhal J, Herold K, Meffre E, Bosenberg M, Kluger HM. B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. Journal For Immunotherapy of Cancer. 7: 153. PMID 31200747 DOI: 10.1186/S40425-019-0613-1  0.659
2018 Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, Perrotti E, Anderson G, Ralabate A, Kluger Y, Wei W, et al. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1800204. PMID 30407895 DOI: 10.1200/Jco.18.00204  0.639
2017 Jilaveanu LB, Puligandla M, Weiss SA, Wang VX, Zito CR, Flaherty KT, Boeke M, Neumeister VM, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas N, Kluger HM. Tumor microvessel density as a prognostic marker in high-risk renal cell carcinoma patients treated on ECOG-ACRIN E2805. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29066509 DOI: 10.1158/1078-0432.Ccr-17-1555  0.658
2017 Kluger HM, Zito CR, Turcu G, Baine M, Zhang H, Adeniran A, Sznol M, Rimm DL, Kluger Y, Chen L, Cohen JV, Jilaveanu LB. PD-L1 Studies Across Tumor Types, its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28223273 DOI: 10.1158/1078-0432.Ccr-16-3146  0.659
2017 Weiss SA, Puligandla M, Jilaveanu L, Haas NB, Wang XV, Zito C, Boeke M, Neumeister V, Manola J, DiPaola RS, Kluger HM. Microvessel density as a prognostic marker in high-risk renal cell carcinoma. Journal of Clinical Oncology. 35: 4565-4565. DOI: 10.1200/Jco.2017.35.15_Suppl.4565  0.659
2015 Baine MK, Turcu G, Zito CR, Adeniran AJ, Camp RL, Chen L, Kluger HM, Jilaveanu LB. Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens. Oncotarget. 6: 24990-5002. PMID 26317902 DOI: 10.18632/Oncotarget.4572  0.675
2015 Kluger HM, Zito CR, Barr ML, Baine MK, Chiang VL, Sznol M, Rimm DL, Chen L, Jilaveanu LB. Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 25788491 DOI: 10.1158/1078-0432.Ccr-14-3073  0.639
2015 Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, Rimm DL, Bosenberg MW, Halaban R, Kluger Y, Kluger HM. PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2138-47. PMID 25316811 DOI: 10.1158/1078-0432.Ccr-14-0861  0.653
2014 Aziz SA, Sznol JA, Albiges L, Zito C, Jilaveanu LB, Camp RL, Escudier B, Kluger HM. Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinoma. Cancer Cell International. 14: 4. PMID 24423208 DOI: 10.1186/1475-2867-14-4  0.644
2014 Jilaveanu LB, Shuch B, Zito CR, Parisi F, Barr M, Kluger Y, Chen L, Kluger HM. PD-L1 expression in clear cell renal cell carcinoma: An analysis of nephrectomy and sites of metastases Journal of Cancer. 5: 166-172. DOI: 10.7150/Jca.8167  0.666
2014 Kluger HM, Halabi S, Solomon NC, Jilaveanu L, Zito C, Sznol J, Nixon AB, Rini BI, Small EJ, George DJ. Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206. Journal of Clinical Oncology. 32: 4532-4532. DOI: 10.1200/Jco.2014.32.15_Suppl.4532  0.654
2013 Jilaveanu LB, Zhao F, Zito CR, Kirkwood JM, Nathanson KL, D'Andrea K, Wilson M, Rimm DL, Flaherty KT, Lee SJ, Kluger HM. Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. Plos One. 8: e69748. PMID 23936348 DOI: 10.1371/Journal.Pone.0069748  0.678
2012 Zito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, Maira SM, Hackl W, Camp R, Kluger HM, Chao HH. Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. Plos One. 7: e31331. PMID 22355357 DOI: 10.1371/Journal.Pone.0031331  0.645
2012 Zito CR, Kluger HM. Immunotherapy for metastatic melanoma. Journal of Cellular Biochemistry. 113: 725-34. PMID 22006439 DOI: 10.1002/Jcb.23402  0.332
2011 Jilaveanu LB, Zito CR, Aziz SA, Chakraborty A, Davies MA, Camp RL, Rimm DL, Dudek A, Sznol M, Kluger HM. In vitro studies of dasatinib, its targets and predictors of sensitivity. Pigment Cell & Melanoma Research. 24: 386-9. PMID 21320292 DOI: 10.1111/J.1755-148X.2011.00835.X  0.611
2010 Aziz SA, Jilaveanu LB, Zito C, Camp RL, Rimm DL, Conrad P, Kluger HM. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 6029-39. PMID 21169255 DOI: 10.1158/1078-0432.Ccr-10-1490  0.664
2010 Chao HH, Zito C, Jilaveanu L, Anagnostou V, Rimm D, Bepler G, Camp R, Kluger HM. Abstract 1787: Dual targeting of PI3K and mTOR results in synergistic growth inhibition in NSCLC cells Cancer Research. 70: 1787-1787. DOI: 10.1158/1538-7445.Am10-1787  0.339
2009 Jilaveanu LB, Zito CR, Aziz SA, Conrad PJ, Schmitz JC, Sznol M, Camp RL, Rimm DL, Kluger HM. C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 5704-13. PMID 19737955 DOI: 10.1158/1078-0432.Ccr-09-0198  0.641
2009 Aziz SA, Davies M, Pick E, Zito C, Jilaveanu L, Camp RL, Rimm DL, Kluger Y, Kluger HM. Phosphatidylinositol-3-kinase as a therapeutic target in melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3029-36. PMID 19383818 DOI: 10.1158/1078-0432.Ccr-08-2768  0.649
2009 Jilaveanu L, Zito C, Lee SJ, Nathanson KL, Camp RL, Rimm DL, Flaherty KT, Kluger HM. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 1076-85. PMID 19188183 DOI: 10.1158/1078-0432.Ccr-08-2280  0.67
2005 Jilaveanu LB, Zito CR, Oliver D. Dimeric SecA is essential for protein translocation. Proceedings of the National Academy of Sciences of the United States of America. 102: 7511-6. PMID 15897468 DOI: 10.1073/Pnas.0502774102  0.681
2005 Zito CR, Antony E, Hunt JF, Oliver DB, Hingorani MM. Role of a conserved glutamate residue in the Escherichia coli SecA ATPase mechanism Journal of Biological Chemistry. 280: 14611-14619. PMID 15710614 DOI: 10.1074/Jbc.M414224200  0.524
2003 Zito CR, Oliver D. Two-stage binding of SecA to the bacterial translocon regulates ribosome-translocon interaction. The Journal of Biological Chemistry. 278: 40640-6. PMID 12907673 DOI: 10.1074/Jbc.M308025200  0.574
Show low-probability matches.